Hatem Soliman

10PUBLICATIONS
57CO-AUTHORS
Tumour immunologyMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Latin and classical Greek languagesHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jun 17, 2025
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.

Denise M Wolf, Christina Yau, Michael Campbell

|Jan 17, 2025
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial.

Alicia F C Okines, Giuseppe Curigliano, Nobumasa Mizuno

|Mar 18, 2023
Author Correction: Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial.

Hatem Soliman, Deanna Hogue, Hyo Han

|Feb 09, 2023
Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial.

Hatem Soliman, Deanna Hogue, Hyo Han

|Aug 09, 2022
Behavioral beliefs about genetic counseling among high-risk Latina breast cancer survivors in Florida and Puerto Rico.

Jessica N Rivera Rivera, Claire C Conley, Eida M Castro-Figueroa

|Feb 05, 2022
Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.

Sara M Tolaney, Masakazu Toi, Patrick Neven

Pageof 2

Frequent Collaborators

3 joint publications

Marie Catherine Lee

2 joint publications

Paula R Pohlmann

2 joint publications

Robert J Weinfurtner

2 joint publications

Blaise Mooney